Paving the way for diversity and inclusion in clinical trials: establishing a platform for improvement
The rarity of each individual rare disease introduces many unique challenges and complexity in clinical research including barriers to achieving representative trial populations and equitable access to trials.Watch the webinar
Examining how the field of clinical research currently approaches diversity and inclusion gives us a baseline understanding on which we can build and make the necessary changes for improvement in the future. ICON looked at the barriers to accessing under-represented subgroups, the regulatory landscape and how organisations are addressing this issue and brings together the findings in this Whitepaper.Read the whitepaper
ICON invited senior executives from Amgen, Sanofi, Eli Lilly and Janssen Research & Development LLC to discuss how decentralised and hybrid clinical trial models can provide increased resilience and how their respective organisations are currently (or likely) to address diversity and inclusion in clinical trials into the future.Read the whitepaper
Clinical trial diversity has been a major topic of discussion for years, but it took the COVID-19 pandemic for the biopharma industry to fully realise the importance of recruiting diverse populations into studies.Watch the webinar
In this blog, we share best practices for a more patient-centric approach to trials as discussed in our webinar to improve accessibility, inclusion and diversity.
The FDA’s new FDORA bill includes provisions intended to improve diversity in trial enrolment through decentralised clinical trials and associated digital health technologies.
Mary O’Reilly and Nikki O’Hanlon discuss the vital role that people leaders play in driving diversity and inclusion within an organisation.
The inclusion of diverse patient populations in clinical trials is nothing new but the topic has risen to the surface in the last year and is now prevalent in high profile conferences and industry exchange.
Everyone knows that increasing the diversity of clinical trial populations is a top priority for global pharma.
There has been a failure to attract enough girls to doing science, technology, engineering and mathematics (STEM) subjects in secondary school and in college.
More so now than ever, the inclusion of more diverse, and often more relevant, study populations is gathering momentum within the clinical trial community.
Leadership within the pharmaceutical industry remains, despite efforts, overwhelmingly white and male.
As a woman of color (WOC) and first-born daughter of immigrants, my life has always had its set of challenges.